[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastrostomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastrostomy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,44,76,98,120,142,174,192,209,234,257,283,306,333],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100543871","ultrasound-for-evaluation-of-percutaneous-g-tube-position-100543871",false,"NCT06361498","Ultrasound for Evaluation of Percutaneous G-tube Position","Accuracy of Ultrasound for the Evaluation of Percutaneous Gastrostomy Tube Position and Leakage","Inclusion Criteria:\n\nAn individual who presents with a dislodged GT and meets one of the following minor criteria:\n\n* Surgical GT placement less than 90 days from presentation\n* Traumatic GT dislodgement\u002Fremoval\n* Recent stoma dilation\n* Clinician uncertainty about position of GT placement\n\nExclusion Criteria:\n\n* An individual \\>18 years of age\n* Acutely ill patients defined as hemodynamically unstable defined as any child who has abnormal vital signs or disruption of vital functions (i.e. airway, breathing, circulation, mental function). Vital signs are based on patient age. Initial assessment of clinical patient stability will be provided by the ordering\u002Freferring provider.","ALL","18 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to compare using ultrasound imaging to look at the position of the gastrostomy tube (GT) against fluoroscopic imaging in pediatric patients who had a recent GT tube replacement.\n\nThe main questions it aims to answer are:\n\n* If ultrasound is just as accurate as fluoroscopy to assess the GT position.\n* If ultrasound takes less time than fluoroscopy to assessing the GT position.\n\nParticipants will be imaging using ultrasound to assess GT positioning before their standard of care fluoroscopic imaging.",[26],"Gastrostomy",[28,29,30],"gastrostomy tube","ultrasound","fluoroscopy","RECRUITING","2026-06-23",{"date":34,"type":35},"2026-06-26","ACTUAL",{"date":37,"type":35},"2024-04-30",{"date":39,"type":20},"2027-06",{"name":41,"class":42},"University of North Carolina, Chapel Hill","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":43},"100551814","stapler-reinforcement-patches-compared-to-standard-staplers-in-gastrojejunostomy-100551814","NCT06464978","Stapler Reinforcement Patches Compared to Standard Staplers in Gastrojejunostomy","The Impact of Stapler Reinforcement Patches Compared to Standard Staplers on Postoperative Complications in Gastrojejunostomy: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 85 years.\n* Pathologically diagnosed with gastric cancer and suitable for distal gastrectomy or subtotal gastrectomy.\n* ECOG performance status of 0 or 1.\n* ASA (American Society of Anesthesiologists) classification of I-III.\n* Voluntary signed informed consent from the participant or their legal representative.\n\nExclusion Criteria:\n\n* Evidence of potential distant metastasis found preoperatively.\n* History of other malignancies diagnosed within the past 5 years, or any malignancy treated with chemotherapy or radiotherapy.\n* Significant contraindications for surgery (e.g., severe liver or kidney dysfunction).\n* Participation in any other clinical trial within the last 6 months.\n* Participants or their legal representatives unwilling to sign the informed consent or comply with the study protocol.","85 Years",{"count":53,"type":20},382,[23],"This is a multi-center, prospective, randomized controlled study aimed at compareing the impact of stapler reinforcement patches versus standard staplers on postoperative complications in gastrojejunostomy.",[57,26,58,59],"Gastric Cancer","Anastomotic Leakage","Postoperative Complications",[61,62,63,64,65],"Stapler Reinforcement Patch","Gastrojejunostomy","Randomized Controlled Trial","Surgical Outcomes","Complication Prevention","2026-03-29",{"date":68,"type":35},"2026-03-31",{"date":70,"type":35},"2024-05-30",{"date":72,"type":20},"2028-12-31",{"name":74,"class":75},"Nanchong Central Hospital","OTHER_GOV",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":43},"100486770","pain-assessment-following-placement-of-a-percutaneous-radiologic-gastrostomy-and-predictive-factors-100486770","NCT05618392","Pain Assessment Following Placement of a Percutaneous Radiologic Gastrostomy and Predictive Factors","DOULEURGPR","Inclusion Criteria:\n\n* Needing a radiologic gastrostomy under local anesthesia\n* Age ≥ 18 years old\n* Read, write and understand the French language\n\nExclusion Criteria:\n\n* Patient under guardianship, deprived of liberty, safeguard of justice\n* Patient presenting a serious psychiatric pathology that does not allow compliance with the completion of the questionnaires (at the discretion of the investigator)\n* Refusal to participate in research",{"count":84,"type":20},50,"OBSERVATIONAL","A 12 months mono-center, descriptive study, to evaluate pain and predictive factors Following placement of percutaneous Radiologic gastrostomy (PRG).\n\nThe primary objective is to evaluate the abdominal pain associated with percutaneous radiologic gastrostomy (PRG) placement.",[88,26],"Gastrostomy Complications","2026-03-17",{"date":91,"type":35},"2026-03-18",{"date":93,"type":35},"2022-12-09",{"date":95,"type":20},"2026-09-01",{"name":97,"class":42},"Centre Hospitalier de Valence",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100455038","trans-pacific-multicenter-collaborative-study-of-minimally-invasive-proximal-versus-total-gastrectomy-for-proximal-gastric-and-gastroesophageal-junction-cancers-100455038","NCT05205343","Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers","Inclusion:\n\n1. Able to speak and read English, Spanish, Japanese or Korean\n2. Participants with a biopsy-confirmed diagnosis of non-metastatic gastric or GEJ adenocarcinoma, who are scheduled to undergo MIPG or MITG for curative-intention\n3. Age ≥ 18\n\nExclusion:\n\n1. Participants with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract\n2. Participants with known narcotic dependence, with average daily dose \\> 5 mg oral morphine equivalent\n3. Participants deemed unable to comply with study and\u002For follow-up procedures, at investigators' discretion\n4. Participants who are pregnant (since are excluded from receiving standard-of-care MIPG or MITG)",{"count":105,"type":20},20,"To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.",[26,108,109],"Gastric","GastroEsophageal Cancer","2026-02-02",{"date":112,"type":35},"2026-02-04",{"date":114,"type":35},"2022-05-11",{"date":116,"type":20},"2026-05-31",{"name":118,"class":42},"M.D. Anderson Cancer Center",4,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":126,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":21,"phases":128,"briefSummary":129,"conditions":130,"keywords":131,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":43},"100359423","feasibility-of-a-constant-pressure-skin-disk-cpsd-in-enteral-tubes-100359423","NCT03959878","Feasibility of a Constant Pressure Skin Disk (CPSD) in Enteral Tubes.","Inclusion Criteria:\n\n* Age greater than or equal to 22 years\n* Undergoing PEG tube or PEJ tube placement\n\nExclusion Criteria:\n\n* History of tobacco or illegal drug use in the past year\n* History of an enteral tube\n* History of gastric surgery (bariatric surgery, Nissen fundoplication, etc.)","22 Years",{"count":105,"type":20},[23],"Researchers are gathering information on one specific part of a feeding tube, known as the adjustable skin disk. Researchers are trying to see if a new type of adjustable skin disk, called a Constant Pressure Skin Disk (CPSD), can safely and effectively support adequate healing, and reduced complication rates.",[26],[132],"Jejunostomy","2026-01-22",{"date":135,"type":35},"2026-01-26",{"date":137,"type":35},"2019-09-30",{"date":139,"type":20},"2026-12",{"name":141,"class":42},"Mayo Clinic",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":149,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":21,"phases":153,"briefSummary":155,"conditions":156,"keywords":159,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":4},"100616304","phase-4-the-use-of-high-bile-binding-foods-to-reduce-upper-gastrointestinal-bile-acid-concentrations-aim-2-100616304","NCT07303868","The Use of High Bile-binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 2)","The Use of High Bile-Binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations: A Novel Intervention for Children at Risk for Aspiration-Associated Complications (Aim 2)","Pediatric patients ages 5 to 21 in the randomized arm Inclusion criteria\n\n* receive at least 80% of their nutritional needs via gastrostomy\n* receive blenderized feeds or will start receiving blenderized feeds\n* have no known allergies to ingredients in blenderized feeds;\n* receive their bolus feeds within 30 minutes or less\n* can receive their feeds by syringe push Exclusion criteria\n* have undergone anti-reflux surgery\n* receive post-pyloric feeds\n* are allergic to any component of the administered diets\n* cannot receive their gastrostomy feeds over 30 minutes\n* require a feeding pump for feed administration (as the H-BBB is too thick for pump administration).\n\nPediatric patients ages 5 to 21 in the observational arm Inclusion\n\n* receive at least 80% of their nutritional needs via gastrostomy\n* are taking an amino acid formula\n* have not undergone antireflux surgery Exclusion\n* have undergone anti-reflux surgery\n* receive post-pyloric feeds\n* are not receiving an amino acid-based formula.","5 Years","21 Years",{"count":152,"type":20},66,[154],"PHASE4","Using a four-week randomized, crossover study design, we will assess the impact of 2 weeks of a high bile acid-binding blenderized diet, compared to 2 weeks of a low bile acid-binding blenderized diet, on gastric and salivary bile acid concentrations within individual participants. Four weeks of an amino acid formula will be a comparator group.",[157,26,158],"Feeding Difficulties","Aspiration",[160,161,162,163],"blenderized","bile acid","gastrostomy","aspiration","NOT_YET_RECRUITING","2025-12-23",{"date":167,"type":35},"2025-12-26",{"date":169,"type":20},"2026-07",{"date":171,"type":20},"2030-08",{"name":173,"class":42},"Boston Children's Hospital",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":149,"maxAge":150,"enrollmentInfo":181,"targetDuration":4,"studyType":21,"phases":183,"briefSummary":184,"conditions":185,"keywords":186,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":187,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":191,"locationsCount":43},"100616294","phase-4-the-use-of-high-bile-binding-foods-to-reduce-upper-gastrointestinal-bile-acid-concentrations-aim-1-100616294","NCT07303738","The Use of High Bile-binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 1)","The Use of High Bile-Binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations: A Novel Intervention for Children at Risk for Aspiration-Associated Complications (Aim 1)","Inclusion Criteria:\n\n* receive at least 80% of their nutritional needs by gastrostomy\n* receive either an amino acid-based formula, an International Dysphagia Diet Standardization Initiative level 4 commercial blend, or a home blend\n* can receive bolus feeds of 240 cc within 30 minutes or less\n\nExclusion Criteria:\n\n* have received a fundoplication\n* receive post-pyloric feeds\n* require medication\u002Fflush administration during the four-hour study period\n* are allergic to any component of the study diets.\n\nTo participate in this study, if patients are taking acid suppression or motility medications (e.g., erythromycin, azithromycin, prucalopride), they will need to stop these at least 72 hours prior to participation in this aim.",{"count":182,"type":20},60,[154],"We will perform an acute physiology study comparing three different diets-an amino acid-based formula, a low bile acid-binding blenderized diet, or a high bile acid-binding blenderized diet administered through gastrostomy tube. We will determine the differences in gastric and salivary bile acid concentrations between participants over the 4 hour post-prandial timeframe.\n\nParticipants who regularly receive an amino acid-based formula will receive an amino acid-based formula during the study and participants who regularly receive a blenderized feed will receive a blenderized feed during the study. Only participants who regularly receive blenderized feeds will be randomized to receive either the high or low bile acid binding blenderized feed.",[157,158,26],[160,161,162,163],{"date":167,"type":35},{"date":189,"type":35},"2025-12-01",{"date":171,"type":20},{"name":173,"class":42},{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":16,"minAge":149,"maxAge":150,"enrollmentInfo":199,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":201,"conditions":202,"keywords":203,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":207,"leadSponsor":208,"locationsCount":4},"100586303","the-use-of-high-bile-binding-foods-to-reduce-upper-gastrointestinal-bile-acid-concentrations-aim-3-100586303","NCT06913621","The Use of High Bile-Binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 3)","The Use of High Bile-Binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations: A Novel Intervention for Children at Risk for Aspiration-Associated Complications (Aim 3)","Inclusion Criteria:\n\n* receive at least 80% of their nutritional needs via gastrostomy\n* receive an International Dysphagia Diet Standardization Initiative level 4 commercial blend, home blend or amino acid-based formula\n* receive their bolus feeds within 30 minutes or less.\n\nExclusion Criteria:\n\n* have undergone anti-reflux surger\n* receive post-pyloric feeds\n* receive regular daily prophylactic antibiotics.",{"count":200,"type":20},138,"Using a longitudinal cohort design, we will compare the impact of a high BA-binding blenderized diet compared to a low BA-binding blenderized diet and an amino acid-based formula, on gastrointestinal and pulmonary hospitalization and emergency room visit rates over six months.",[157,26,158],[160,161,162,163],{"date":205,"type":35},"2025-12-30",{"date":169,"type":20},{"date":171,"type":20},{"name":173,"class":42},{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":16,"minAge":215,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":21,"phases":218,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":43},"100518184","oral-supplementation-of-glutamine-on-gastric-cancer-patients-after-gastrectomy-100518184","NCT06027242","Oral Supplementation of Glutamine on Gastric Cancer Patients After Gastrectomy","Inclusion Criteria:\n\n* adult gastric cancer receiving gastrectomy\n\nExclusion Criteria:\n\n* Hepatic insufficiency\n* Renal insufficiency\n* can not tolerate oral or enteral feeding 7 days after gastrectomy\n* can not receive computed tomograph\n* can not waer the wearable devices","20 Years",{"count":217,"type":20},120,[23],"Glutamine has the potentials of immunomodulation and adjustment of protein metabolism. The primary objective of this study is to evaluate the efficacy of glutamine on sarcopenia in gastric adenocarcinoma patients undergoing gastrectomy. The secondary endpoints, including the physical activity, weight loss, and nutritional profiles, will be evaluated among these patients.",[57,221,26],"Immunonutrition",[223,224,225],"Gastric cancer","Gastrectomy","sarcopenia","2025-12-16",{"date":165,"type":35},{"date":229,"type":35},"2023-02-21",{"date":231,"type":20},"2026-08-30",{"name":233,"class":42},"National Taiwan University Hospital",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":16,"minAge":241,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":21,"phases":245,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":43},"100602118","eoi-block-for-laparoscopic-gastrostomy-100602118","NCT07119346","EOI Block for Laparoscopic Gastrostomy","Effect of Ultrasound-guided External Oblique Intercostal Fascial Plane Block in Pediatric Patients Undergoing Laparoscopic Gastrostomy: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Scheduled for laparoscopic gastrostomy at Seoul National University Children's Hospital\n\nAge ≥3 and \\\u003C18 years\n\nExclusion Criteria:\n\n* Unstable vital signs\n\nContraindications to ropivacaine or opioids\n\nSevere hepatic or renal dysfunction\n\nOther investigator-determined ineligibility","3 Years","17 Years",{"count":244,"type":20},40,[23],"This randomized controlled trial will evaluate the efficacy of ultrasound-guided external oblique intercostal fascial plane (EOI) block in reducing intraoperative and postoperative pain in pediatric patients undergoing laparoscopic gastrostomy under general anesthesia. Forty patients aged 3-18 years will be randomly allocated to receive either bilateral EOI block with 0.25% ropivacaine or sham block with normal saline. Primary outcome is percent change in heart rate at surgical incision. Secondary outcomes include intraoperative fentanyl use, perioperative analgesic requirements, postoperative pain scores (r-Face, Legs, Activity, Cry, Consolability(r-FLACC) and Pediatric Pain Profile), Analgesia Nociception Index values, and analgesia-related adverse events.",[26],"2025-08-11",{"date":250,"type":35},"2025-08-13",{"date":252,"type":20},"2025-08",{"date":254,"type":20},"2028-05",{"name":256,"class":42},"Seoul National University Hospital",{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":21,"phases":266,"briefSummary":267,"conditions":268,"keywords":271,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":281,"locationsCount":43},"100590401","nasopharyngeal-airway-combined-with-nasal-high-flow-oxygen-therapy-during-painless-gastroscopy-in-obesity-patients-100590401","NCT06966934","Nasopharyngeal Airway Combined With Nasal High-flow Oxygen Therapy During Painless Gastroscopy in Obesity Patients","The Application of Nasopharyngeal Airway Combined With Nasal High-flow Oxygen Therapy During Painless Gastroscopy in Patients With Obesity","Inclusion Criteria:\n\n1. Patients undergoing painless gastroscopy;\n2. Patients with an age greater than 18 years old;\n3. American Society of Anesthesiologists (ASA) physical status classification from Grade I to Grade III;\n4. Body Mass Index (BMI) greater than 28 kg\u002Fm²\n\nExclusion Criteria:\n\n1. Patients with contraindications to endoscopic procedures or those who refuse sedation\u002Fanesthesia;\n2. Patients allergic to propofol, eggs, soybeans, milk, etc.;\n3. Patients with gastrointestinal tract obstruction and gastric emptying disorders;\n4. Patients with acute pharyngitis, tonsillitis, and upper respiratory tract infections;\n5. Patients in the acute exacerbation stage of respiratory diseases such as asthma, bronchitis, and chronic obstructive pulmonary disease (COPD);\n6. Patients with acute arrhythmia and those with severe heart diseases (congenital diseases, valvular diseases);\n7. Patients with severe hepatic and renal insufficiency who require alternative treatment;\n8. Patients with severe mental disorders who need medications to control their symptoms;\n9. Patients with moderate or above anemia, abnormal coagulation function, and hematological diseases;\n10. Patients with nasal cavity lesions leading to severe nasal congestion;\n11. Pregnant and lactating patients.",{"count":265,"type":20},364,[23],"Gastroscopy is a commonly used, direct, and reliable method for screening and diagnosing digestive tract diseases. However, as an invasive examination, it can cause adverse reactions such as pain, nausea, vomiting, and choking cough in patients. Compared with ordinary gastroscopy, painless gastroscopy offers higher comfort and satisfaction for patients and greater convenience for endoscopists during operation.\n\nThe most common complication of painless gastroscopy diagnosis and treatment is hypoxia. High-flow nasal cannulala (HFNC) provides a higher oxygen concentration and flow rate than an ordinary nasal catheter. It has the functions of heating and humidifying, which can relieve the pressure on the nasal mucosa cilia, keep the airway unobstructed and moist, and reduce the risk of epistaxis. Due to changes in airway anatomical structures such as fat accumulation in the head and neck and hyperplasia of oropharyngeal soft tissues, obese patients are more prone to hypoxia during gastroscopy under sedation. Therefore, HFNC is often used to reduce the occurrence of hypoxia.\n\nThe nasopharyngeal airway (NPA) is used to maintain the patency of the upper respiratory tract and is suitable for patients with spontaneous breathing but partial obstruction of the upper respiratory tract. It is worth exploring how effective the combination of HFNC and NPA is in improving hypoxemia in obese patients during sedation.",[269,270,26],"Hypoxia","Obesity",[272,273,274],"Obese patients","sedative gastroscopy","high-flow nasal oxygen therapy","2025-07-17",{"date":277,"type":35},"2025-07-22",{"date":279,"type":35},"2025-05-14",{"date":116,"type":20},{"name":282,"class":42},"Nanjing First Hospital, Nanjing Medical University",{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":21,"phases":292,"briefSummary":293,"conditions":294,"keywords":295,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":43},"100561065","high-flow-nasal-oxygen-therapy-in-obese-patients-undergoing-sedative-gastroscopy-100561065","NCT06585306","High-flow Nasal Oxygen Therapy in Obese Patients Undergoing Sedative Gastroscopy","Study on the Safety of High-flow Nasal Oxygen Therapy With Different Flow Rates in Obese Patients Undergoing Sedative Gastroscopy","Inclusion Criteria:\n\n1. Patients undergoing sedative gastroscopy\n2. Aged over 18.\n3. ASA classification I-III\n4. Interincisal distance \\>6.5cm, no micrognathia, limited mouth opening and limited cervical spine movement\n5. Compliance with ethics, patient willing to participate in the trial, signed informed consent form\n\nExclusion Criteria:\n\n1. Contraindications for endoscopic procedures or patients refusing sedation\u002Fanesthesia.\n2. Patients with allergies to propofol, eggs, soybeans, or milk.\n3. Patients with gastrointestinal obstruction and gastric emptying disorders.\n4. Patients with acute pharyngitis, tonsillitis, and upper respiratory tract infections.\n\n5: Patients with acute exacerbations of respiratory diseases such as asthma, bronchitis, and COPD. 6. Patients with acute arrhythmias and severe heart disease (congenital, valvular disease). 7. Patients requiring replacement therapy for severe liver or kidney dysfunction.\n\n8\\. Patients with severe mental illnesses requiring medication to control symptoms.\n\n9\\. Patients with moderate to severe anemia, coagulation disorders, and hematological diseases. 10. Patients with severe nasal congestion caused by nasal cavity lesions. 11. Pregnant and lactating patients.",{"count":291,"type":20},864,[23],"Obese patients often have fat accumulation in the head and neck, increased soft tissue in the oropharynx, decreased lung compliance, decreased lung volume and residual volume, and some obese patients also suffer from obstructive sleep apnea. Therefore, obese patients may experience hypoxemia during sedative gastroscopy. High-flow nasal cannula oxygen therapy (HFNC) can provide patients with high-flow (20-70 L\u002Fmin) and adjustable oxygen concentration (21%-100%) through a special nasal prong catheter. It has the function of warming and humidifying the air, relieving pressure on the nasal mucosa, maintaining airway patency and moisture, reducing the risk of nasal bleeding. In addition, HFNC can generate positive airway pressure (3-7 cmH2O), increase end-expiratory volume, help with alveolar recruitment, prevent atelectasis, and reduce shunts. The flow rate of HFNC is positively correlated with the nasopharyngeal pressure. At a flow rate of 50 L\u002Fmin, the nasopharyngeal pressure can exceed 3 cmH2O. Obese patients are prone to upper airway obstruction under sedation or anesthesia. The use of HFNC at 70 L\u002Fmin perioperatively can reduce hypoxemia in patients, but discomfort in the nasopharynx may occur at this flow rate. The optimal flow rate for clinical use of HFNC has not been established. Meta-analysis shows that when the oxygen flow rate during painless esophagogastroduodenoscopy is greater than 30 L\u002Fmin, it can significantly reduce the incidence of hypoxemia in patients. Therefore, for obese patients undergoing painless esophagogastroduodenoscopy, the investigators propose using HFNC at three different flow rates: 30 L\u002Fmin, 50 L\u002Fmin, and 70 L\u002Fmin, to provide guidance on the optimal flow rate for clinical use of HFNC.",[269,270,26],[272,273,296],"HFNC","2025-03-30",{"date":299,"type":35},"2025-04-01",{"date":301,"type":35},"2024-10-23",{"date":303,"type":20},"2025-10-20",{"name":305,"class":42},"XiaoLiang Wang",{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":313,"enrollmentInfo":314,"targetDuration":4,"studyType":21,"phases":316,"briefSummary":317,"conditions":318,"keywords":321,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":4},"100533698","billroth-ii-with-braun-anastomosis-after-radical-distal-gastrectomy-for-gastric-cancer-100533698","NCT06229197","Billroth II With Braun Anastomosis After Radical Distal Gastrectomy for Gastric Cancer","Billroth II With Braun Anastomosis Versus Billroth II Anastomosis After Radical Distal Gastrectomy With D2 Lymphadenectomy for Gastric Cancer: a Randomized Controlled Trial","Inclusion criteria\n\nTo be enrolled, participants must be phase I-III patients with initial treatment of radical distal gastrectomy and satisfying the following inclusion criteria:\n\n1. Histologically proven stage I-III gastric cancer, evaluated as radically resectable\n2. No synchronous or metachronous cancers\n3. Patients have signed informed consent forms\n4. Age 18-80 years old\n5. No malfunction of cardio-pulmonary, liver, and kidney, ECOG score 0-1\n6. No emergency surgery needed\n\nExclusion criteria\n\nPatients will be excluded according to the following criteria:\n\n1. Pregnant or lactating women\n2. Distant metastasis to the liver, lung, bone, supraclavicular lymph nodes, pelvic, or ovarian species and peritoneal dissemination\n3. Ascites or cachexia\n4. Suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, poorly controlled hypertension or diabetes\n5. Participation in other clinical trials 4 weeks before the enrollment of this trial or still participating in other trials\n6. Mental illness\n7. Surgical history whose influence has not been eliminated\n8. History of another gastric or esophageal malignancy, including stromal tumor, sarcoma, lymphoma, and carcinoid\n9. Active infection with a fever of over 38°C\n10. Poor compliance\n11. Not suitable for this trial because of other clinical or laboratory conditions determined by the researchers","80 Years",{"count":315,"type":20},176,[23],"The primary aim of this trial is to rigorously evaluate the comparative benefits and potential risks associated with Billroth II reconstruction with Braun anastomosis versus Billroth II reconstruction alone following distal gastrectomy with D2 lymphadenectomy in patients diagnosed with gastric cancer. This assessment focuses on delineating the therapeutic efficacy, safety profile, and overall clinical outcomes of these two surgical approaches in treating this condition.",[57,319,320,26],"Surgery","Anastomosis",[57,26,322,323],"Billroth II","Braun Anastomosis","2024-01-18",{"date":326,"type":35},"2024-01-29",{"date":328,"type":20},"2024-02-01",{"date":330,"type":20},"2027-12-31",{"name":332,"class":42},"Sichuan University",{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":341,"enrollmentInfo":342,"targetDuration":4,"studyType":21,"phases":344,"briefSummary":345,"conditions":346,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":43},"100370996","rct-early-feeding-after-peg-placement-100370996","NCT04110613","RCT: Early Feeding After PEG Placement","A Randomized Controlled Trial to Reduce Periprocedural Fasting in Ventilated Trauma and Surgical Intensive Care Patients","PEG","Inclusion Criteria:\n\n* Adult subjects over 18 years of age\n* Negative pregnancy test for women participants of child-bearing age\n* Mechanically ventilated surgical and trauma patients with clinical indication for PEG tube placement\n* Tolerating tube feeds at goal prior to procedure\n\nExclusion Criteria:\n\n* Patients with aberant gastrointestinal anatomy\n* Patients with gastrointestinal motility disorders\n* Patients with feeding intolerance prior to PEG tube procedure\n* Pregnant women, children, or other vulnerable populations\n* Clinical contraindications for PEG tube placement\n* PEG performed in setting other than ICU at bedside","100 Years",{"count":343,"type":20},1200,[23],"Randomized controlled trial to establish evidence on which to base timing of enteral feeding after bedside PEG placement in ventilated Trauma and Surgical ICU patients.",[347,348,26,349,350,319,351],"Critical Illness","Malnutrition","Procedural Sequelae","Trauma","Mechanical Ventilation","2021-10-18",{"date":354,"type":35},"2021-10-26",{"date":356,"type":35},"2019-09-19",{"date":358,"type":20},"2026-09-30",{"name":360,"class":42},"Carilion Clinic"]